Hostname: page-component-cd9895bd7-gxg78 Total loading time: 0 Render date: 2024-12-26T20:31:54.810Z Has data issue: false hasContentIssue false

Therapeutic strategies in atypical depression. A German perspective

Published online by Cambridge University Press:  16 April 2020

HJ Möller*
Affiliation:
University of Bonn, Department of Psychiatry, Sigmund-Freud Strasse 25, D-5300, Bonn I, Germany
Get access

Summary

In Germany a major distinction is made between endogenous and neurotic depression. While traditionally neurotic depression was seen as being amenable only to psychotherapy, there is an increasing tendency to treat neurotic patients presenting the full depressive syndrome with antidepressant drugs. Those psychiatrists who are aware of the concept of atypical depression in the stricter sense (anxiety-depression, depression with reversed somatic symptoms, etc) tend to treat these patients with monoamine oxidase inhibitors. The diagnosis of “dysthymia”, Possibly equivalent to “neurotic depression”, has not yet come into common usage. While the term “neurasthenia” is traditional, general Practitioners prefer other designations; treatment involves supportive psychotherapy, benzodiazepines and sedative antidepressants. Mixed anxiety-depression is treated with anxiolytic antidepressants, sedatives or, for the milder cases, with low-dose neuroleptics. This indication for neuroleptics is controversial, and a treatment protocol has been codified for use by the general practitioners so as to avoid the potential major adverse reactions seen with the class. The new concept of recurrent brief depression is confined to academic milieu, where treatment is the same as for unipolar depression.

Type
Research Article
Copyright
Copyright © European Psychiatric Association 1993

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bochnik, HJKoch, H (1990) Die Nervenarzt-Studie: Praxen, Kompetenzen, Patienten. Deutscher Ärzte-Verlag, KölnGoogle Scholar
Hippius, H (1988) Warum verordnet man niedrig dosierte Neuroleptika?In: Therapie mit Neuroleptika-Niedrigdosierung (Hippius, HLaakmann, G eds). Perimed Erlangen S 79Google Scholar
Howland, RH (1991) Pharmacotherapy of dysthymia: a review. J Clin Psychopharmacol 11, 2CrossRefGoogle ScholarPubMed
Linden, M (1987) Phase-IV-Forschung: Antidepressiva in der Nervenpraxis, Sonderband für Forum Galenus Mannheim. Springer-Verlag, BerlinCrossRefGoogle Scholar
Möller, HJ (1986) Neuroleptika als Tranquilizer: Indikationen und Gefahren. Med Klinik 81, 385388Google Scholar
Möller, HJ (1990) Indications for a low-dose neuroleptic therapy in non-psychiatric, psychiatric diseases. Clin Neuropharmacol 13, suppl 2Google Scholar
Paykel, ESFreeling, PHollyman, JA (1988) Are tricyclic antidepressants useful for mild depression? A placebo controlled trial. Pharmacopsychiatrie 21, 1518CrossRefGoogle ScholarPubMed
Paykel, ESWhite, JL (1989) A European study of views on the use of monoamine oxidase inhibitors. Br J Psychiatry 155, suppl 6, 917CrossRefGoogle Scholar
Wittchen, HUAhmoie Essau, C v Zerssen, Det al (1992) Lifetime and six-month prevalence of mental disorders in the Munich follow-up study. Eur Arch Psychiatry Clin Neurosci 241, 247258CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.